SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-275395
Filing Date
2022-11-02
Accepted
2022-11-02 07:06:37
Documents
14
Period of Report
2022-11-02
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d408934d8k.htm   iXBRL 8-K 23679
2 EX-99.1 d408934dex991.htm EX-99.1 601856
6 GRAPHIC g408934g1101052008293.jpg GRAPHIC 2073
  Complete submission text file 0001193125-22-275395.txt   799658

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA hznp-20221102.xsd EX-101.SCH 2876
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE hznp-20221102_lab.xml EX-101.LAB 17169
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE hznp-20221102_pre.xml EX-101.PRE 10802
8 EXTRACTED XBRL INSTANCE DOCUMENT d408934d8k_htm.xml XML 3295
Mailing Address CONNAUGHT HOUSE, 1ST FLOOR 1 BURLINGTON ROAD DUBLIN L2 4
Business Address CONNAUGHT HOUSE, 1ST FLOOR 1 BURLINGTON ROAD DUBLIN L2 4 011-353-1-772-2100
Horizon Therapeutics Public Ltd Co (Filer) CIK: 0001492426 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35238 | Film No.: 221352267
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences